⚕ GalenOps field
←

SITE014-0280

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-01-27

AEs
8
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Diarrhoea — outcome: UNKNOWN; onset 2023-02-12 (study day 2); relationship: N

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-04-03 (study day 52); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-14 (study day 63); relationship: not assessed

severe serious assessed

Grade 3 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-04-19 (study day 68); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-10 (study day 89); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 192); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-06 (study day 269); relationship: Y

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-22 (study day 285); relationship: Y

Data queries

No data queries.